Skip to content
‹ Back to IndustriesHealthcare

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · DiaceuticsBristol Myers SquibbPrecision for All Strategic CollaborationPrecision Medicine Commercialization
Share
Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Key takeaways

01

Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.

02

In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.

03

Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Diaceutics surveyed 125 US pharma leaders, who gave converting diagnosis into treatment an average score of 7.5 out of 10 for its importance to future commercial success. Asked how well their own organizations turn diagnostic insights into coordinated action, they scored themselves at just 5.2.

That gap comes from a new Diaceutics survey of 125 US pharma leaders. Diaceutics describes itself as an intelligence and engagement company for diagnostic-driven therapies. Of the respondents, 85% hold director-level roles or higher. A majority, 56.8%, strongly agreed that turning diagnoses into treatment now matters as much as traditional brand promotion. Diaceutics CEO Ryan Keeling said the industry is improving at producing intelligence, but not always at acting on that intelligence at the moment it counts.

Most surveys find some distance between ambition and execution. This one is worth reading for where the scores fall, especially next to Diaceutics' own real-world data on lung cancer. Read together, they could suggest that the weak point now sits at the treatment decision rather than at testing.

Self-ratings slide down the pathway

Respondents scored several capabilities on a 10-point scale.

How US pharma leaders rate diagnosis-to-treatment capabilities (out of 10)
Diaceutics survey of 125 US pharma leaders, November 2026 · © MarketScaleDownload chart

Asked how confident they are in identifying eligible patients, respondents gave a score of 6.6 out of 10. Their organizations' visibility across the patient journey, from testing to the start of treatment, scored 5.4. Nearly half of respondents (48.8%) called it a significant challenge when identified patients do not start appropriate therapy.

The question on barriers fills in some detail. Respondents were asked what keeps eligible patients from appropriate therapy, and access and reimbursement topped the list at 51.2%. Late testing followed at 47.2%, then failure to identify patients at 44.8%, and test results that don't lead to treatment at 36.8%. Because those answers sit so close together, respondents appear to see the problem as spread across several points, not concentrated in one.

Where lung cancer patients now drop out

Diaceutics' updated Clinical Practice Gaps report, released in May 2026, offers real-world data on one disease. It used the seven-step framework from the company's 2022 study in the Journal of Clinical Oncology. The data covered more than 35,800 newly diagnosed US patients with advanced non-small cell lung cancer, comparing 2019 with 2023.

Diaceutics' Clinical Practice Gaps report found that overall patient loss across the precision medicine pathway remained virtually unchanged at 65.1% in 2023 versus 64.4% in 2019. Patient losses earlier in the pathway declined, which the report described as positive diagnostic progress. Patient loss at the point of treatment decision rose from 29.2% to 43.3%, and the largest gap now occurs at that stage.

How oncologists use biomarker results

86%
of oncologists form treatment plans before full biomarker results are available
43%
consistently wait for results before starting first-line therapy
More than half
do not consistently act on biomarker report recommendations

Diaceutics Clinical Practice Gaps report, May 2026

If 86% of oncologists form treatment plans before full biomarker results are available, a faster or more accurate test could do little for a patient whose plan is already set. Susanne Munksted, Diaceutics' chief precision medicine officer, called the downstream gap a translation problem: testing has improved, and the losses have moved to the decision point. The report said its findings highlight a growing disconnect between expanding diagnostic capabilities and treatment decision-making, driven by increasing complexity and time pressure on clinicians.

Respondents rated their confidence in identifying eligible patients at 6.6 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. That could suggest the weaker self-rating lines up with the point of treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.

The match has limits. Only 36.8% of surveyed leaders named results not leading to treatment as a barrier, the lowest share of the four options, even though the treatment decision is the biggest loss point in the lung data. Part of the gap is scope: the survey covers every therapy area, and the lung report covers one cancer. The barriers respondents ranked higher could also show up as a missed treatment decision, since a late test result is easy to miss when most plans are already formed. For an oncology team, the lung data is the sharper benchmark. For a team in another disease area, it's a hypothesis to check against its own patient data.

Diagnostic planning moves ahead of launch

Diaceutics used the survey findings to shape its Precision for All Strategic Collaboration. The new initiative gathers senior leaders from pharmaceutical companies to work on narrowing the distance between scientific innovation and its real-world impact on patients. In a first discussion, representatives from several top 20 pharma organizations pointed to the need to build diagnostic planning into therapy development and commercialization much earlier, instead of tackling testing infrastructure and adoption problems after launch.

Participants also named problems no single manufacturer controls: testing practices that vary, patient pathways that are fragmented, and weak coordination between the groups involved. They saw a role for AI and advanced analytics in helping clinicians sort through more and more complex diagnostic and treatment information. They attached two conditions: the data underneath has to be reliable, and the tools have to fit into clinical workflows.

Andrew Witriol, Vice President, US Oncology Marketing at Bristol Myers Squibb, was a participant in the discussion. He said data and AI can help companies see where patients get lost along the way, and that closing those gaps takes collaboration across the healthcare system. Read next to the lung data, that view makes sense: if most treatment plans form before biomarker results are in, the decision point may sit outside any one manufacturer's reach.

Measuring loss one step at a time

For brand and commercial operations leads running a therapy that depends on a diagnostic, the visibility score may deserve the closest look. Respondents scored their ability to see the patient journey, from testing to the start of treatment, at 5.4 out of 10. A team that can't follow patients from test to treatment start can't tell whether they're lost at identification, at testing or at the prescribing decision. The lung data shows those steps can move in opposite directions while the overall loss rate stays flat.

Check whether the brand dashboard reports patient loss separately for identification, testing and the treatment decision, or as one blended conversion rate. Diaceutics' lung cancer data shows that from 2019 to 2023, a flat overall rate hid a treatment-decision step that got worse.

Representatives from several top 20 pharma organizations took part in an initial discussion in Diaceutics' Precision for All Strategic Collaboration. They concluded that diagnostic planning needs to be built into therapy development and commercialization much earlier, instead of dealing with testing infrastructure and adoption challenges after launch. That could put the question into launch plans for assets still in development. For teams with a precision therapy already on the market, a step-by-step view of patient loss could be the starting point.

Diaceutics said it will keep expanding its real-world analysis to better understand and address what drives treatment decision failure. Through the ongoing Precision for All Strategic Collaboration, it aims to bring more industry leaders together to find practical solutions to shared challenges. The number to watch is the 5.2. Operators tracking it may find that a shift in that self-score is an early signal that work on data, AI and earlier diagnostic planning is paying off, ahead of any change in real-world patient loss at the treatment decision.

Featured companies

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

Memorial Hermann emergency physicians using Ambience Healthcare's AI documentation generated about $37,500 more in yearly productivity value than non-users. That figure is gross and comparative. It comes from billing data annualized over 160 shifts and excludes software costs, so buyers must build the cost side themselves.

  • 01Memorial Hermann's $37,500 per emergency physician is gross: the gap in work RVUs per clinical hour between AI documentation users and non-users, annualized over 160 ten-hour shifts, before any software or implementation cost.
  • 02Divided out, that gain comes to roughly $234 a shift or about $23 per clinical hour, a practical yardstick to hold against any all-in per-physician cost quote.
  • 03When a vendor puts fees at risk against outcomes, the comparison group, billing source and acuity adjustment become contract terms, because they decide what counts as a gain worth paying for.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512